PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04329494 |
|
Recruitment Status :
Recruiting
First Posted : April 1, 2020
Last Update Posted : May 6, 2022
|
Sponsor:
City of Hope Medical Center
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
City of Hope Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the lining of the abdominal cavity (peritoneal carcinomatosis). Chemotherapy drugs, such as cisplatin, doxorubicin, oxaliplatin, leucovorin, fluorouracil, mitomycin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. PIPAC is a minimally invasive procedure that involves the administration of intraperitoneal chemotherapy. The study device consists of a nebulizer (a device that turns liquids into a fine mist), which is connected to a high-pressure injector, and inserted into the abdomen (part of the body that contains the digestive organs) during a laparoscopic procedure (a surgery using small incisions to introduce air and to insert a camera and other instruments in the abdominal cavity for diagnosis and/or to perform routine surgical procedures). Pressurization of the liquid chemotherapy through the study device results in aerosolization (a fine mist or spray) of the chemotherapy intra-abdominally (into the abdomen). Giving chemotherapy through PIPAC may reduce the amount of chemotherapy needed to achieve acceptable drug concentration, and therefore potentially reduces side effects and toxicities.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Clinical Stage IV Gastric Cancer AJCC v8 Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Stage IVB Gastric Cancer AJCC v8 Malignant Uterine Neoplasm Metastatic Appendix Carcinoma Metastatic Colorectal Carcinoma Metastatic Gastric Carcinoma Metastatic Malignant Neoplasm in the Peritoneum Metastatic Malignant Solid Neoplasm Metastatic Ovarian Carcinoma Pathologic Stage IV Gastric Cancer AJCC v8 Peritoneal Carcinomatosis Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8 Stage IV Appendix Carcinoma AJCC v8 Stage IV Colorectal Cancer AJCC v8 Stage IV Ovarian Cancer AJCC v8 Stage IV Uterine Corpus Cancer AJCC v8 Stage IVA Appendix Carcinoma AJCC v8 Stage IVA Colorectal Cancer AJCC v8 Stage IVA Ovarian Cancer AJCC v8 Stage IVA Uterine Corpus Cancer AJCC v8 Stage IVB Appendix Carcinoma AJCC v8 Stage IVB Colorectal Cancer AJCC v8 Stage IVB Ovarian Cancer AJCC v8 Stage IVB Uterine Corpus Cancer AJCC v8 Stage IVC Appendix Carcinoma AJCC v8 Stage IVC Colorectal Cancer AJCC v8 | Procedure: Biopsy Drug: Cisplatin Drug: Doxorubicin Drug: Fluorouracil Device: Intraperitoneal Chemotherapy Drug: Irinotecan Drug: Leucovorin Drug: Mitomycin Drug: Oxaliplatin Other: Quality-of-Life Assessment Other: Questionnaire Administration | Phase 1 |
Show detailed description
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 49 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) |
| Actual Study Start Date : | August 21, 2020 |
| Estimated Primary Completion Date : | February 5, 2023 |
| Estimated Study Completion Date : | February 5, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Ovarian cancer
MedlinePlus related topics:
Stomach Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm I (PIPAC, doxorubicin, cisplatin)
Patients with ovarian, uterine, or gastric cancer, undergo PIPAC with doxorubicin IP, followed by cisplatin IP. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
|
Procedure: Biopsy
Undergo biopsy
Other Names:
Drug: Cisplatin Given via PIPAC
Other Names:
Drug: Doxorubicin Given via PIPAC
Other Names:
Device: Intraperitoneal Chemotherapy Undergo PIPAC
Other Name: Intraperitoneal Therapy Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies |
|
Experimental: Arm II (PIPAC, oxaliplatin, leucovorin, fluorouracil)
Patients with colorectal or appendiceal cancer undergo PIPAC with oxaliplatin IP. For cycles 2 and 3, patients receive leucovorin IV over 10 minutes and fluorouracil IV over 15 minutes 1-24 hours before undergoing PIPAC. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
|
Procedure: Biopsy
Undergo biopsy
Other Names:
Drug: Fluorouracil Given IV
Other Names:
Device: Intraperitoneal Chemotherapy Undergo PIPAC
Other Name: Intraperitoneal Therapy Drug: Leucovorin Given IV
Other Name: Folinic acid Drug: Oxaliplatin Given via PIPAC
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies |
|
Experimental: Arm III (PIPAC, mitomycin, FOLFIRI)
Patients with colorectal or appendiceal cancer who have undergo at least 4 months (or 8 cycles) of first-line standard of care chemotherapy but have not progressed on second line chemotherapy undergo PIPAC with mitomycin IP. Patients also receive standard of care irinotecan IV over 90 on day 1, leucovorin IV over 30 minutes on day 1, and fluorouracil IV on days 1-2 during weeks 2, 4, 8, 10, 14 and 16. Treatment repeats every 4-6 weeks for up to 3 cycles in the absence of disease progression or unacceptable toxicity.
|
Procedure: Biopsy
Undergo biopsy
Other Names:
Drug: Fluorouracil Given IV
Other Names:
Device: Intraperitoneal Chemotherapy Undergo PIPAC
Other Name: Intraperitoneal Therapy Drug: Irinotecan Given IV Drug: Leucovorin Given IV
Other Name: Folinic acid Drug: Mitomycin Given via PIPAC
Other Names:
Other: Quality-of-Life Assessment Ancillary studies
Other Name: Quality of Life Assessment Other: Questionnaire Administration Ancillary studies |
Primary Outcome Measures :
- Dose limiting toxicities [ Time Frame: Up to 18 weeks ]Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v) 5.0. Summarized by type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study treatment, and reversibility or outcome.
- Incidence of adverse events [ Time Frame: From day 1 of protocol therapy until week 18 ]Assessed using CTCAE v.5.0. Summarized by grade and attribution. Post-surgical complications will be assessed by Clavien-Dindo classification.
Secondary Outcome Measures :
- Percentage of evaluable patients who have achieved complete response (CR), partial response (PR), or stable disease (SD) [ Time Frame: At baseline, following the second cycle (week 10), and 6 weeks after completing treatment (at 18 weeks/off-study) ]Assessed by Response Evaluation Criteria in Solid Tumors criteria version 1.1 via computed tomography (CT) scan. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach by Clopper and Pearson.
- Percentage of evaluable patients who have achieved CR, PR, or SD [ Time Frame: At the time of laparoscopy (or CT imaging if laparoscopy is not planned during surgery) ]Assessed by Peritoneal Carcinomatosis Index. The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach by Clopper and Pearson.
- Percentage of evaluable patients who have achieved a decrease in Peritoneal Regression Grading Score over successive biopsies [ Time Frame: Up to 18 weeks ]The proportion of successes will be estimated by the number of successes divided by the total number of evaluable patients. Confidence intervals for the true success proportion will be calculated according to the approach by Clopper and Pearson.
- Progression-free survival [ Time Frame: Time from first pressurized intraperitoneal aerosolized chemotherapy (PIPAC) procedure, assessed up to 1 year ]Described using the Kaplan-Meier method.
- Post-surgical complications [ Time Frame: At 4 weeks after each PIPAC ]Assessed by Clavien-Dindo classification. Results will be strictly descriptive in nature.
- PIPAC technical failure rate [ Time Frame: Up to 3 years ]
- Functional status [ Time Frame: Up to 18 weeks ]Measured by the number of daily steps before and after treatments (Vivofit 4 wristband pedometer - Garmin Company).
- Cytoreductive surgery rate (Arm 3) [ Time Frame: Up to 18 weeks ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Documented informed consent of the participant and/or legally authorized representative
- Patients must have histologically confirmed ovarian, uterine, gastric, appendiceal or colorectal cancer with PC
- Prior IP chemotherapy is permitted
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) =< 2
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Platelets >= 100,000/mm^3
- Hemoglobin >= 9 g/dl
- Serum total bilirubin =< 1.5 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) and aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.5 x ULN, unless liver metastases (Arm 1) are present or unless patients is know to have chronic liver disease (hepatitis) in which case AST and ALT must be =< 5 x ULN
- Alkaline phosphatase =< 2 x ULN
- Serum creatinine (sCr) =< 1.5 x ULN, or creatinine clearance (Ccr) >= 40 ml/min as calculated by the Cockcroft-Gault formula
- No contraindications for a laparoscopy
- The peritoneal disease does not have to be measurable by RECIST 1.1 but needs to be visible on cross sectional imaging or diagnostic laparoscopy
- Patients must have progressed on at least one evidence-based chemotherapeutic regimen (Arm 1 and 2). For Arm 3, patients should have stable or responsive disease on at least 4 months first-line systemic chemotherapy
- For patients with a known history of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a known history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Women of childbearing potential (WOCBP) and male patients with WOCBP partner must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 12 weeks after the last dose of investigational product in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Post menopause is define as:
- Amenorrhea >= 12 consecutive months without another cause or
- For women with irregular menstrual periods and on hormone replacement therapy (HRT), a documented serum follicle stimulating hormone (FSH) level > 35 mIU/mL
- Women who are using oral contraceptives, other hormonal contraceptives (vaginal products, skin patches, or implanted or injectable products), or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy, or are practicing abstinence or where their partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential
-
INCLUSION TO PROCEED WITH PIPAC: Laparoscopy findings must meet all of the below criteria in order to proceed to PIPAC:
- PIPAC access is feasible
- There is room for aerosol therapy
- There is no evidence of impending bowel obstruction
- =< 5 L of ascites
- Not a candidate for cytoreduction and HIPEC
Exclusion Criteria:
-
Gastric and colorectal/appendiceal:
- Extra-peritoneal metastatic disease
- Arm 1 (ovarian, uterine, gastric): Previous treatment with maximum cumulative doses of doxorubicin, daunorubicin, epirubicin, idarubicin, and/or other anthracyclines and anthracenediones
- Arm 2 (colorectal/appendiceal): Known dihydropyrimidine dehydrogenase deficiency (DPD) deficiency
- Arm 2 (colorectal/appendiceal): Bowel obstruction requiring nasogastric tube, percutaneous endoscopic gastrostomy or exclusive total parenteral nutrition
- Arm 2 (colorectal/appendiceal): Prior unanticipated severe reaction or hypersensitivity to platinum based compounds
- Arm 2 (colorectal/appendiceal): Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia, hearing loss, or non-clinically significant laboratory abnormalities. Grade 2 peripheral neuropathy is permitted
- Arm 2 (colorectal/appendiceal): Life expectancy of less than 6 months
- Arm 2 (colorectal/appendiceal): Chemotherapy or surgery within the last 4 weeks prior to enrollment (6 weeks for prior bevacizumab therapy). Five half-lives for other anti-cancer agents
- Arm 2 (colorectal/appendiceal): Previous anaphylactic reaction to the chemotherapy drug used
- Arm 2 (colorectal/appendiceal): Patients may not be receiving any other investigational or concurrent anti-cancer agents
- Arm 2 (colorectal/appendiceal): Ascites due to decompensated liver cirrhosis; portal vein thrombosis
- Arm 2 (colorectal/appendiceal): Simultaneous tumor debulking with gastrointestinal resection
- Arm 2 (colorectal/appendiceal): Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, severe renal impairment, myelosuppression, or severe hepatic impairment
- Arm 2 (colorectal/appendiceal): Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system
- Arm 2 (colorectal/appendiceal): Involvement in the planning and conduct of the study
- Arm 2 (colorectal/appendiceal): Pregnancy
- Arm 2 (colorectal/appendiceal): Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Arm 2 (colorectal/appendiceal): New York Heart Association (NYHA) class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months
- Arm 2 (colorectal/appendiceal): Major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
- Arm 2 (colorectal/appendiceal): Exclusive total parenteral nutrition
- Arm 2 (colorectal/appendiceal): Prior intra-abdominal aerosol chemotherapy
- Arm 3 (colorectal/appendiceal): Progression on first- AND second-line systemic therapy
- Arm 3 (colorectal/appendiceal): Hematologic toxicities requiring significant dose reductions while on systemic chemotherapy
- Arm 3 (colorectal/appendiceal): Intolerance to prior 5-FU at 2400mg/m^2 IV every 2 weeks or to irinotecan at 180mg/m^2. Intolerance is defined as the need of significant dose reduction or treatment interruption of > 1 week due to toxicity
- Arm 3 (colorectal/appendiceal): Known DPD deficiency
- Arm 3 (colorectal/appendiceal): Bowel obstruction requiring nasogastric tube, percutaneous endoscopic gastrostomy or exclusive total parenteral nutrition
- Arm 3 (colorectal/appendiceal): Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1), with the exception of alopecia, hearing loss, or non-clinically significant laboratory abnormalities. Grade 2 peripheral neuropathy is permitted
- Arm 3 (colorectal/appendiceal): Life expectancy of less than 6 months
- Arm 3 (colorectal/appendiceal): Chemotherapy or surgery within the last 2 weeks prior to enrollment (6 weeks for prior bevacizumab therapy). Five half-lives for other anti-cancer agents
- Arm 3 (colorectal/appendiceal): Previous anaphylactic reaction to the chemotherapy drug used
- Arm 3 (colorectal/appendiceal): Patients may not be receiving any other investigational anti-cancer agents
- Arm 3 (colorectal/appendiceal): Ascites due to decompensated liver cirrhosis; portal vein thrombosis
- Arm 3 (colorectal/appendiceal): Simultaneous tumor debulking with gastrointestinal resection
- Arm 3 (colorectal/appendiceal): Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, severe myocardial insufficiency, recent myocardial infarction, severe arrhythmias, severe renal impairment, myelosuppression, or severe hepatic impairment
- Arm 3 (colorectal/appendiceal): Immunocompromised patients such as those with an immunosuppressive medication or a known disease of the immune system
- Arm 3 (colorectal/appendiceal): Involvement in the planning and conduct of the study
- Arm 3 (colorectal/appendiceal): Pregnancy
- Arm 3 (colorectal/appendiceal): Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Arm 3 (colorectal/appendiceal): New York Heart Association (NYHA) class 3 or 4; myocardial infarction, acute coronary syndrome, diabetes mellitus with ketoacidosis or chronic obstructive pulmonary disease (COPD) requiring hospitalization in the preceding 6 months
- Arm 3 (colorectal/appendiceal): Major systemic infection requiring antibiotics 72 hours or less prior to the first dose of study drug
- Arm 3 (colorectal/appendiceal): Exclusive total parenteral nutrition
- Arm 3 (colorectal/appendiceal): Prior intra-abdominal aerosol chemotherapy
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04329494
Locations
| United States, California | |
| City of Hope Medical Center | Recruiting |
| Duarte, California, United States, 91010 | |
| Contact: Thanh H. Dellinger 626-218-1379 tdellinger@coh.org | |
| Principal Investigator: Thanh H. Dellinger | |
| United States, Florida | |
| Mayo Clinic in Florida | Recruiting |
| Jacksonville, Florida, United States, 32224-9980 | |
| Contact: Amit L. Merchea 904-953-2596 Merchea.AmitL@mayo.edu | |
| Principal Investigator: Amit L. Merchea | |
| United States, New York | |
| Northwell Health Cancer Institute at Huntington | Recruiting |
| Greenlawn, New York, United States, 11740 | |
| Contact: Richard L. Whelan 212-434-4860 rwhelan1@northwell.edu | |
| Principal Investigator: Richard L. Whelan | |
Sponsors and Collaborators
City of Hope Medical Center
National Cancer Institute (NCI)
Investigators
| Principal Investigator: | Thanh H Dellinger, MD | City of Hope Medical Center | |
| Principal Investigator: | Mustafa Raoof, MD | City of Hope Medical Center |
| Responsible Party: | City of Hope Medical Center |
| ClinicalTrials.gov Identifier: | NCT04329494 |
| Other Study ID Numbers: |
19184 NCI-2020-01254 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ) 19184 ( Other Identifier: City of Hope Medical Center ) P30CA033572 ( U.S. NIH Grant/Contract ) |
| First Posted: | April 1, 2020 Key Record Dates |
| Last Update Posted: | May 6, 2022 |
| Last Verified: | May 2022 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | Yes |
| Device Product Not Approved or Cleared by U.S. FDA: | Yes |
| Product Manufactured in and Exported from the U.S.: | No |
Additional relevant MeSH terms:
|
Carcinoma Neoplasms Colorectal Neoplasms Ovarian Neoplasms Carcinoma, Ovarian Epithelial Stomach Neoplasms Peritoneal Neoplasms Uterine Neoplasms Appendiceal Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
Digestive System Diseases Gastrointestinal Diseases Colonic Diseases Intestinal Diseases Rectal Diseases Endocrine Gland Neoplasms Ovarian Diseases Adnexal Diseases Genital Neoplasms, Female Urogenital Neoplasms Endocrine System Diseases Gonadal Disorders Stomach Diseases Abdominal Neoplasms Peritoneal Diseases |